相关实验视频

Updated: Sep 12, 2025

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

沃尔登斯特罗姆巨球蛋白血症患者的奥比努祖马布诱导和维持:一个开放的,单臂的第二阶段研究

Tomasz Wróbel¹, Elżbieta Kalicińska¹, Jan Maciej Zaucha²

¹Wrocław Medical University, Wrocław, Poland.

EClinicalMedicine

|August 4, 2025

概括

奥比努图祖马布在治疗沃尔登斯特罗姆巨球蛋白血症方面表现出有效性,随着时间的推移,反应会加深. 这种单剂疗法在复发或耐药病例中提供了可管理的安全性.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床药理学临床药理学

背景情况:

沃尔登斯特罗姆巨型球蛋白血症 (WM) 仍然是一个重要的治疗挑战,特别是在患有并发病的老年患者中.
现有的复发性或耐火性WM治疗方法往往存在局限性,需要新的治疗策略.
CD20抗原是B细胞恶性瘤的验证标,包括WM.

研究的目的:

评估奥比努图祖马布作为单一药物的疗效和安全性,用于诱导和维护疗法,在患有复发性或耐火性WM的患者中.
评估该患者群体中obinutuzumab治疗的反应深度和长期结果.

主要方法:

一项开放的,单臂的,第二阶段研究招募了23名患有复发性/耐药性WM的患者,并证实了CD20表达.
患者接受了Obinutuzumab 1000 mg的诱导疗法,持续6个周期,随后进行了2年的维持疗法.
主要终点是最佳整体响应率 (BOR),次要终点包括整体响应率 (ORR),无进展生存率 (PFS) 和整体生存率 (OS).

主要成果:

最好的整体应答率 (BOR) 为65.2%,在基线IgM≥40g/L的患者中,BOR高于75.0%.
在研究结束时,整体响应率 (ORR) 达到65%,治疗结束后非常好的部分响应 (VGPR) 和完全缓解 (CR) 显著加深.
无进展生存率为65%,总生存率为74%;3级以上不良事件发生在65.2%的患者中,其中34.8%与治疗有关.

结论:

奥比努图祖马布在复发性/耐药性WM中显示出作为单一诱导和维持剂的显著活性.
治疗后反应加深,表明持续的疗效和长期疾病控制的潜力.
奥比努图祖马布的安全性概况是可控的,支持在这个具有挑战性的患者群体中使用它.

关键词:

这种CD20抗体是CD20抗体.免疫治疗是一种免疫疗法.淋巴质细胞性淋巴瘤是淋巴细胞性淋巴瘤.欧比努祖马布单独治疗的治疗方法沃尔登斯特罗姆的巨型球蛋白血症

更多相关视频

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...